Partial Dopamine Agonists for Substance Use Disorder Craving
Aripiprazole can be used to reduce cravings in substance use disorder at a starting dose of 5 mg orally once daily, titrated to 10-15 mg/day based on response, though evidence remains limited and this represents off-label use.
Mechanism and Rationale
Aripiprazole functions as a partial dopamine D2 receptor agonist, which theoretically normalizes dopamine neurotransmission in the mesolimbic reward pathway without the adverse effects of full agonists or antagonists 1, 2. This unique pharmacological profile may reduce substance cravings by modulating dopamine release—increasing it in areas of low tone while decreasing it where tone is excessive 3, 2.
The anterior cingulate cortex appears to be a key brain region where aripiprazole reduces substance cravings by altering neural activity 4.
Dosing Strategy
Initial Dosing
- Start with 5 mg orally once daily 5
- Can be given without regard to meals 6
- Reduce to 2.5 mg in older or frail patients 5
Titration
- Target dose: 10-15 mg/day for most patients 6
- Do not increase dose before 2 weeks (time to steady state) 6
- The effective dose range is 10-30 mg/day, though higher doses (>15 mg) have not demonstrated superior efficacy 6
Maintenance
- Continue at the lowest effective dose that controls cravings 5
- Periodically reassess need for continued treatment 6
Evidence by Substance Type
Alcohol Use Disorder
- In patients with bipolar disorder and alcohol dependence, aripiprazole significantly reduced both dollars spent on alcohol (p=0.042) and alcohol craving (p=0.003) over 12 weeks 3
- Psychiatric symptoms also improved concurrently on depression and mania rating scales 3
Cocaine Use Disorder
- Aripiprazole significantly reduced cocaine craving (p=0.014) in patients with bipolar/schizoaffective disorder, though actual cocaine use did not significantly decrease 3
Cannabis Use Disorder
- In a real-world cohort of 96 patients with schizophrenia spectrum disorders and cannabis use disorder, aripiprazole (both oral and long-acting injectable forms) improved psychotic symptoms and reduced substance craving over 18 months 7
- Long-acting injectable aripiprazole showed superior effects on craving compared to oral formulations 7
Important Caveats and Limitations
The evidence base remains insufficient for definitive recommendations 1. Most studies are small, open-label, lack placebo controls, and involve patients with comorbid psychiatric disorders rather than isolated substance use disorders 3, 1.
Common Side Effects
- Akathisia and insomnia, particularly at treatment initiation 8
- Headache, agitation, anxiety, dizziness, drowsiness 5
- Generally non-sedating with low risk of weight gain and metabolic effects 8
- Lower risk of extrapyramidal symptoms compared to typical antipsychotics 5
Drug Interactions
- Reduce dose by 50% when co-administered with strong CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine) or CYP3A4 inhibitors (itraconazole, clarithromycin) 6
- Reduce dose to 25% when combining strong CYP2D6 and CYP3A4 inhibitors 6
- Double the dose over 1-2 weeks when co-administered with strong CYP3A4 inducers (carbamazepine, rifampin) 6
- Reduce dose by 50% in known CYP2D6 poor metabolizers 6
Clinical Context
Behavioral therapy remains essential. Combined cognitive behavioral therapy (CBT) and pharmacotherapy produces superior outcomes compared to usual care plus pharmacotherapy alone in substance use disorders 5. Aripiprazole should be viewed as an adjunct to, not a replacement for, evidence-based psychosocial interventions 5.
The primary care approach to substance misuse emphasizes motivational interviewing techniques and advising abstinence for patients with substance abuse 5. Aripiprazole may be particularly useful when persistent cravings undermine recovery efforts despite behavioral interventions.